Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
ERJ Open Research|January 10, 2024
Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristicsDavid R W Jayne, Benjamin Terrier, Bernhard Hellmich, et al.
ACR Open Rheumatology|June 13, 2023
Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic PhenotypeBenjamin Terrier, David R W Jayne, Bernhard Hellmich, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 24, 2021
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREOIan D Pavord, Kenneth R Chapman, Mona Bafadhel, et al.
Allergy and Asthma Proceedings|July 3, 2019
Association of depressive symptoms with health status and markers of uncontrolled severe asthmaSandhya Khurana, Jeffrey M Lyness, Stephen Mallett, et al.
The New England Journal of Medicine|September 9, 2014
Mepolizumab treatment in patients with severe eosinophilic asthmaHector G Ortega, Mark C Liu, Ian D Pavord, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 10, 2022
Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polypsLarry Borish, Noam A Cohen, Geoffrey Chupp, et al.
The Lancet. Respiratory Medicine|April 19, 2021
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trialJoseph K Han, Claus Bachert, Wytske Fokkens, et al.
Allergy|August 17, 2021
From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseasesIan D Pavord, Elisabeth H Bel, Arnaud Bourdin, et al.
The Journal of Allergy and Clinical Immunology|September 21, 2020
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trialFlorence Roufosse, Jean-Emmanuel Kahn, Marc E Rothenberg, et al.
The Journal of Allergy and Clinical Immunology|October 26, 2018
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthmaSumita Khatri, Wendy Moore, Peter G Gibson, et al.
Pageof 7